Published in Immunity on February 01, 1997
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A (1998) 3.35
Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol (2002) 2.17
Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A (1998) 2.11
T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol (2004) 2.11
Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics (2006) 1.93
Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses. Retrovirology (2011) 1.80
HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A (1998) 1.63
Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest (2003) 1.63
Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med (2001) 1.50
PRAME is a golgi-targeted protein that associates with the Elongin BC complex and is upregulated by interferon-gamma and bacterial PAMPs. PLoS One (2013) 1.46
PRAME expression in hairy cell leukemia. Leuk Res (2008) 1.41
CD8⁺ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. J Clin Invest (2011) 1.40
Current concepts of metastasis in melanoma. Expert Rev Dermatol (2008) 1.34
Duplication and positive selection among hominin-specific PRAME genes. BMC Genomics (2005) 1.29
Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J Clin Invest (2009) 1.28
Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med (2001) 1.26
PRAME expression and clinical outcome of breast cancer. Br J Cancer (2008) 1.26
IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest (2002) 1.24
HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells. Proc Natl Acad Sci U S A (1998) 1.22
The expansion of the PRAME gene family in Eutheria. PLoS One (2011) 1.21
Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J Immunol (2002) 1.16
The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood (2009) 1.11
Allorecognition in the Tasmanian devil (Sarcophilus harrisii), an endangered marsupial species with limited genetic diversity. PLoS One (2011) 1.11
Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin-like receptors. Blood (2006) 1.09
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08
In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med (1999) 1.08
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2007) 1.07
Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med (2016) 1.03
The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters. EMBO J (2011) 1.03
Identification of HLA-E-specific alloreactive T lymphocytes: a cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells. Proc Natl Acad Sci U S A (2002) 0.98
Major histocompatibility complex class I molecules modulate activation threshold and early signaling of T cell antigen receptor-gamma/delta stimulated by nonpeptidic ligands. J Exp Med (1997) 0.97
T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med (2005) 0.93
PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clin Cancer Res (2016) 0.93
Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol Immunother (2011) 0.92
The human EKC/KEOPS complex is recruited to Cullin2 ubiquitin ligases by the human tumour antigen PRAME. PLoS One (2012) 0.90
Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin Cancer Res (2013) 0.89
Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J (2011) 0.88
Pure red cell aplasia and lymphoproliferative disorders: an infrequent association. ScientificWorldJournal (2012) 0.88
Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer (2010) 0.88
The tortoise and the hare: slowly evolving T-cell responses take hastily evolving KIR. Immunology (2010) 0.87
Profiling of Hodgkin's lymphoma cell line L1236 and germinal center B cells: identification of Hodgkin's lymphoma-specific genes. Mol Med (2003) 0.87
PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions. Oral Oncol (2012) 0.87
Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells. J Immunol (2009) 0.86
Molecular Insights on Post-chemotherapy Retinoblastoma by Microarray Gene Expression Analysis. Bioinform Biol Insights (2013) 0.86
Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). Clin Exp Immunol (2000) 0.84
Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. Cancer J (2013) 0.82
Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. J Pathol Clin Res (2015) 0.82
Human Tumor Antigens and Cancer Immunotherapy. Biomed Res Int (2015) 0.81
Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia. Biomark Insights (2007) 0.81
Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization. Br J Cancer (2000) 0.81
Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma? Biomark Med (2013) 0.81
Priming of immune responses against transporter associated with antigen processing (TAP)-deficient tumours: tumour direct priming. Immunology (2009) 0.81
A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. J Clin Invest (2017) 0.80
PRAME Gene Expression in Acute Leukemia and Its Clinical Significance. Cancer Biol Med (2012) 0.80
Germ cell proteins in melanoma: prognosis, diagnosis, treatment, and theories on expression. J Skin Cancer (2012) 0.80
Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells. PLoS One (2013) 0.79
External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas. BMC Cancer (2009) 0.79
Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. Oncotarget (2016) 0.79
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open (2016) 0.78
Preferentially Expressed Antigen of Melanoma Prevents Lung Cancer Metastasis. PLoS One (2016) 0.78
Up-regulation of activating and inhibitory NKG2 receptors in allogeneic and autologous hematopoietic stem cell grafts. J Exp Clin Cancer Res (2015) 0.78
Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer. World J Gastroenterol (2004) 0.78
A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors. J Immunother (2015) 0.78
Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics. Int J Clin Exp Pathol (2015) 0.78
UPDATE ON VACCINE DEVELOPMENT FOR RENAL CELL CANCER. Open Access J Urol (2010) 0.77
PRAME as diagnostic marker and as regulator for cell fate decisions in germ cell cancers. Br J Cancer (2016) 0.77
Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma. Mod Pathol (2014) 0.77
Differential expression of PRAMEL1, a cancer/testis antigen, during spermatogenesis in the mouse. PLoS One (2013) 0.77
Vaccines as consolidation therapy for myeloid leukemia. Expert Rev Hematol (2011) 0.77
Squamous tissue lymphocytes in the esophagus of controls and patients with reflux esophagitis and Barrett's esophagus are characterized by a non-inflammatory phenotype. PLoS One (2014) 0.77
Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State. Vaccines (Basel) (2015) 0.77
Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget (2015) 0.77
Update on vaccine development for renal cell cancer. Open Access J Urol (2010) 0.76
PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo. Int J Clin Exp Pathol (2015) 0.76
Atlas on substrate recognition subunits of CRL2 E3 ligases. Oncotarget (2016) 0.75
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res (2017) 0.75
Subtractive screening of genes involved in cellular senescence. Cytotechnology (2001) 0.75
Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes. Oncol Lett (2017) 0.75
Identification of Preferentially Expressed Antigen of Melanoma as a Potential Tumor Suppressor in Lung Adenocarcinoma. Med Sci Monit (2016) 0.75
Retinoids: novel immunomodulators and tumour-suppressive agents? Br J Pharmacol (2012) 0.75
PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget (2016) 0.75
Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. Oral Oncol (2016) 0.75
Impact of Preferentially Expressed Antigen of Melanoma on the Prognosis of Hepatocellular Carcinoma. Gastrointest Tumors (2016) 0.75
In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). Oncotarget (2017) 0.75
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. JAMA Ophthalmol (2017) 0.75
Opa interacting protein 5 acts as an oncogene in bladder cancer. J Cancer Res Clin Oncol (2017) 0.75
Current status of engineered T-cell therapy for synovial sarcoma. Immunotherapy (2016) 0.75
HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses. Oncoimmunology (2017) 0.75
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol (2001) 7.07
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47
Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci U S A (1986) 5.60
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 5.03
A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol (1985) 4.71
Subpopulations of human T cells identified by receptors for immunoglobulins and mitogen responsiveness. J Immunol (1976) 4.64
Direct demonstration of the clonogenic potential of every human peripheral blood T cell. Clonal analysis of HLA-DR expression and cytolytic activity. J Exp Med (1983) 4.47
Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol (1996) 4.24
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med (1994) 4.20
NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med (1998) 3.83
DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol (1999) 3.76
Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity (1995) 3.72
Inactivation of ribosomes in vitro by colicin E 3 . Proc Natl Acad Sci U S A (1971) 3.53
[Teratocarcinoma of the mouse: isolation, culture and properties of pluripotential cells]. Ann Microbiol (Paris) (1973) 3.46
The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med (1991) 3.22
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19
Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science (1995) 3.19
BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity (1995) 3.13
Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med (1998) 3.09
Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med (1999) 3.08
An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res (2001) 3.08
Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics (1994) 2.93
A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med (1992) 2.92
Inactivation of ribosomes in vitro by colicin E 3 and its mechanism of action. Proc Natl Acad Sci U S A (1972) 2.88
A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med (1995) 2.88
Two subsets of human T lymphocytes expressing gamma/delta antigen receptor are identifiable by monoclonal antibodies directed to two distinct molecular forms of the receptor. J Exp Med (1988) 2.86
Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med (1995) 2.75
p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med (1997) 2.70
The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A (1996) 2.63
Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer (1987) 2.50
Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics (1992) 2.45
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci U S A (1989) 2.40
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A (1995) 2.34
Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proc Natl Acad Sci U S A (1988) 2.34
Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell (1989) 2.31
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med (1996) 2.30
Tumor antigens recognized by T cells. Immunol Today (1997) 2.28
cDNA cloning of murine interleukin-HP1: homology with human interleukin 6. Eur J Immunol (1988) 2.26
CD3-negative lymphokine-activated cytotoxic cells express the CD3 epsilon gene. J Immunol (1988) 2.22
Allorecognition by NK cells: nonself or no self? Immunol Today (1992) 2.21
Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol (1994) 2.19
NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med (1999) 2.17
Quantitative assessment of the pool size and subset distribution of cytolytic T lymphocytes within human resting or alloactivated peripheral blood T cell populations. J Exp Med (1983) 2.16
T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor. J Exp Med (1988) 2.14
Specific lysis of allogeneic cells after activation of CD3- lymphocytes in mixed lymphocyte culture. J Exp Med (1988) 2.14
Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest (1997) 2.11
Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity (2000) 2.10
Alloantigen recognition by two human natural killer cell clones is associated with HLA-C or a closely linked gene. Proc Natl Acad Sci U S A (1992) 2.08
Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J Exp Med (1992) 2.04
B cell growth and differentiation activity of interleukin-HP1 and related murine plasmacytoma growth factors. Synergy with interleukin 1. Eur J Immunol (1988) 1.99
Human natural killer cell receptors for HLA-class I molecules. Evidence that the Kp43 (CD94) molecule functions as receptor for HLA-B alleles. J Exp Med (1994) 1.98
Human natural killer cell receptors and co-receptors. Immunol Rev (2001) 1.94
Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol (2001) 1.93
Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. J Immunol (1997) 1.92
Purification and properties of colicin E3 immunity protein. J Biol Chem (1974) 1.92
Involvement of T44 molecules in an antigen-independent pathway of T cell activation. Analysis of the correlations to the T cell antigen-receptor complex. J Exp Med (1985) 1.92
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med (1980) 1.91
Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases. J Immunol (1996) 1.90
Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med (1983) 1.89
Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) (2007) 1.89
Surface markers of cloned human T cells with various cytolytic activities. J Exp Med (1981) 1.87
Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci U S A (1977) 1.85
Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature (1985) 1.85
Antigen recognition by human T cell receptor gamma-positive lymphocytes. Specific lysis of allogeneic cells after activation in mixed lymphocyte culture. J Exp Med (1988) 1.84
Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol (1997) 1.84
Human natural killer cells: origin, clonality, specificity, and receptors. Adv Immunol (1994) 1.83
Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer (1992) 1.83
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol (1994) 1.83
Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer (1995) 1.81
Human T lymphocyte subpopulations: studies of the mechanism by which T cells bearing Fc receptors for IgG suppress T-dependent B cell differentiation induced by pokeweed mitogen. J Immunol (1979) 1.80
Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer (1989) 1.80
Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev (1997) 1.77
LAGE-1, a new gene with tumor specificity. Int J Cancer (1998) 1.76
Selection of highly transfectable variant from mouse mastocytoma P815. Somat Cell Mol Genet (1985) 1.76
A monoclonal antibody specific for a common determinant of the human T cell receptor gamma/delta directly activates CD3+WT31- lymphocytes to express their functional program(s). J Exp Med (1988) 1.71
The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. Eur J Immunol (1997) 1.69